Connect Conference & Show Floor Educational Sessions

View, browse and sort the list of Connect Conference sessions and show floor programming by pass type, track, and format. Please note, all Connect Conference delegates have access to InformEx Connect and CPhI Connect programming. Seating is first come, first serve, so please arrive early to sessions that you would like to attend. Sessions are subject to change.

To learn more about the Connect Conference program, click here.

All SessionsSpeakersMy Schedule
View Sessions As:
  • Peter D. Senter Ph.D.Vice President, Chemistry and Senior Distinguished FellowSeattle Genetics

    Peter Senter joined Seattle Genetics in August 1998 and now serves as Vice President of Chemistry. His group carries out research in anticancer drug design, antibody-drug conjugate technologies for cancer therapy, and protein glycoengineering. Several of the molecules generated in Dr. Senter's lab have entered clinical trials, and two of them have been approved: Adcetris for relapsed Hodgkin lymphoma and certain non-Hodgkin lymphoma, and Etopophos for solid tumor therapy. Dr. Senter has authored more than 150 scientific publications and holds more than 40 issued patents. He received an A.B. in Biochemistry from the University of California, Berkeley, a Ph.D. in Chemistry from the University of Illinois, and did postdoctoral research at the Max Planck Institute of Experimental Medicine in Göttingen, Germany. He is the Senior Editor of Molecular Cancer Therapeutics, on the Editorial Advisory Boards of several other journals, and serves as an Affiliate Professors at the University of Washington Department of Bioengineering and the University of Southern California School of Pharmacy.